Fast Facts

We are a commercial-stage, global pharmaceutical company with one FDA-approved drug in three oncology indications and three  additional drug candidates in clinical development.

We have been working for over 10 years to advance research and development in cancer therapeutics.

Our internationally diverse team speaks 23 languages, with headquarters outside Boston and satellite offices in Israel and Germany.

We are an immigrant female-founded biotech company where over 50% of our leadership positions are filled by women. 

We have been serving patients since 2012 when our novel drug selinexor first entered clinical trials and we continue to be inspired by these courageous patients and their families.

Our Mission

We seek to foster scientific creativity with pioneering technologies and developmental approaches within an innovative culture that will accelerate first-in-class small molecule modulators of nuclear transport into effective therapeutics for life-threatening conditions.

At Karyopharm, we support a culture of innovation, courage, urgency, resiliency and energy (ICURE) with our employees and collaborators.

Our Blueprint For Success

Innovation

We encourage employees to develop creative, yet practical ideas that don’t simply rely on things that have been done in the past.

Courage

We challenge the norms to solve problems and advance science in order produce the best outcomes for patients.

Urgency

We approach our tasks with drive, passion and dedication with
an understanding that patients battling cancer
are relying on us every day.

Resilience

We remain committed to persevere even
in the face of challenges and adversity.

Energy

We approach opportunities and tackle challenges with a great sense of enthusiasm and determination.

Our Science

Science and innovation are the core principles by which we operate. We are pioneering novel science to harness each cell’s own natural defense mechanisms to prevent the initiation and growth of cancers. We are the leader in innovative science to advance cancer therapy by targeting the regulation of critical proteins that need to be located in a cell’s nucleus in order to function properly. This approach is synergistic with current anti-cancer treatments making it an ideal partner for future combination therapy approaches.

Our Approach

Our clinical development strategy for XPOVIO® has been to innovate with the purpose of helping difficult-to-treat patient populations and then expanding into larger patient groups and tumor types. The mechanisms of action of our novel nuclear export inhibitors target a foundational aspect of cancer biology which may allow them to be used against a very wide variety of different tumors. Our development began in hematologic malignancies and we have expanded our clinical trials into a variety of solid tumors.

We see our pipeline of products as a critical partner of choice to be combined with other cancer medicines in a host of different types of cancer and other serious diseases.

Our Story

We began in 2008 with a vision of pioneering a new approach to treating patients with cancer and other serious diseases. Our novel approach to treating cancer involves targeting a cancer cell’s nucleus to prevent the development of a disease. For this reason, our name is based on the suffix ‘karyo’, which means nucleus.

In 2019, we received our first accelerated approval in penta-refractory multiple myeloma. We received a second accelerated approval in 2020 for relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL). 

We received an expanded approval for XPOVIO in December of 2020 to now include patients with multiple myeloma as early as first relapse.

In 2020, we also had a successful phase 3 study in heavily pretreated patients with a rare tumor type called dedifferentiated liposarcoma.

We are undertaking numerous clinical trials with a bright future of potential FDA approvals yet to come.

Karyopharm works every day, innovating the science needed to improve the lives of patients with cancer.

Below is a brief timeline of our company history.

  • 2008
    Company founded by Drs. Sharon Shacham and Michael Kauffman to develop potential new drugs which target the regulation of certain proteins in the cell nucleus as a way to treat cancer and other diseases
  • 2010
    First evidence of anti-cancer activity of selinexor in mice
  • 2012
    First patient treated with selinexor in a clinical trial
  • 2013
    Karyopharm becomes publicly traded company with shares listed on Nasdaq
  • 2019
    Selinexor receives first accelerated approval by FDA for patients with relapsed or refractory multiple myeloma (a form of blood cancer) under the brand name XPOVIO
  • 2020
    XPOVIO receives second accelerated approval by FDA for patients with relapsed or refractory diffuse large B-cell lymphoma (another form of blood cancer)

    Company completes successful phase 3 study in heavily pretreated dedifferentiated liposarcoma.

    On December 18, XPOVIO received expanded approval in multiple myeloma, which fundamentally changes the commercial profile of XPOVIO and Karyopharm. The previous approval limited XPOVIO to roughly 6,000 patients with penta-refractory disease. The expanded approval increases XPOVIO as an option to more than 39,000 patients who have received at least one prior therapy (including the original 6,000). 
  • 2021 And Beyond
    Karyopharm hopes to expand XPOVIO’s approved indications in the U.S. into earlier stage disease, in combination with other anticancer drugs, and in new tumor types (particularly solid tumor indications).

    In March, the European Commission (EC) granted conditional marketing authorization for NEXPOVIO® (selinexor), in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.  Selinexor has also recently received regulatory approval in Israel.

    Our team works relentlessly every day to develop innovative drugs to help treat patients with certain blood cancers or solid tumor malignancies. Since our beginning, we have been committed to changing lives and defeating cancer through science and innovation.